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Background: There has been increased interest in pain neuroscience education 
(PNE) as a therapeutic approach for the management of fibromyalgia (FM).
Methods: A multicentre randomized, open- label, controlled trial was conducted to 
assess the effectiveness of a structured group intervention based on PNE in patients 
with FM. A total of 139 patients were included in the study and randomized to the 
intervention group (7 group sessions of education in neurobiology of pain) or to the 
control group (treatment as usual only). The primary outcome was the improvement 
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1 |  INTRODUCTION
Fibromyalgia (FM), a disorder of chronic widespread pain accom-
panied by numerous other symptoms that causes significant func-
tional impairment, is currently considered to fall under the umbrella 
of central sensitivity syndromes. In these syndromes, there is an 
amplification of sensory stimuli and a permanent activation of the 
alarm system, with sustained motor, autonomic and neuroendocrine 
reactions (Hawkins, 2013; Yunus, 2007). At present, there are no 
medications with FM- specific approval in Europe, and therapies are 
focused on the relief of symptoms and improvement of quality of 
life and functioning (Macfarlane et al., 2017). Nonpharmacological 
interventions, such as physical exercise (Bidonde et al., 2017) and 
cognitive behavioural therapy (Bernardy et  al.,  2018), have pro-
vided evidence- based benefits (García et al., 2018) and are recom-
mended by guidelines (Macfarlane et al., 2017).
Recently, growing evidence supports the use of pain neuro-
science education (PNE) as an educational strategy that focuses 
on teaching subjects especially those with chronic pain, about 
the neurobiological and neurophysiological processes involved 
in their pain experience (Brodal, 2017; Butler & Moseley, 2003; 
Geneen et  al.,  2015; Gifford,  1998; Gomez- Arguelles 
et al., 2018; Moseley, 2003b). Knowing and understanding the 
mechanisms behind the perception of pain may reduce the as-
sessment of threat and change the patient's cognition of the pain 
process and the attitudes related to it (Moseley, 2003a, 2003b). 
The use of PNE in patients with FM has shown promising re-
sults (Amer- Cuenca et al., 2019; Van Ittersum et al., 2014; Van 
Oosterwijck et al., 2013) but the reported experience is still lim-
ited. This randomized controlled clinical trial investigated the 
effectiveness of a structured group intervention based on PNE 
for improving pain and functioning in patients with FM as com-
pared with treatment as usual.
2 |  METHODS
2.1 | Trial design
We conducted a multicentre, randomized, open- label, con-
trolled trial in the primary care setting at the Basque country 
in Spain. The main goal of the study was to evaluate the ef-
fectiveness at 1 year of a structured education intervention 
in neurobiology of pain in patients diagnosed with FM as 
compared with a control group of patients that continued 
only with their usual treatments. The time frame of the study 
was 1 year. All patients provided written informed consent 
before enrolment. The study protocol was designed follow-
ing the SPIRIT statement (https://www.spiri t- state ment.org/) 
and was approved by the Ethics Committee of the Basque 
country (file no. PI2016097). This trial was registered at 
ClinicalTrials.gov (identifier NCT03947502).
Funding information
None of the authors received any funding 
to support this work. Partial reduction 
of routine work tasks of the principal 
investigator, MJ Barrenengoa- Cuadra, 
was supported by a grant from OSI Bilbao 
Basurto Osakidetza, Basque country, Spain 
(the grant was paid to the Health Service to 
substitute MJ Barrenengoa- Cuadra while 
research work).
of functional status and pain measured with the Fibromyalgia Impact Questionnaire 
(FIQ), and secondary outcomes were the reduction in the impact of pain and other 
symptoms (catastrophizing, anxiety and depression) and number of patients reaching 
no worse than moderate functional impairment (FIQ score <39). Differences between 
groups were calculated by linear mixed- effects (intention- to- treat approach) and me-
diational models through path analyses.
Results: At 1 year, improvements in FIQ scores were higher in the intervention group 
with moderate or high effect size, and decreases of ≥20% in 69.1% of patients (20.9% 
in the control group) and of ≥50% in 39.7% (4.5% in the control group). Also, 52.9% 
of patients had a FIQ <39 points (13.4% in the control group).
Conclusions: In this sample of patients with FM, the improvement in quality of life 
and control of symptoms obtained by adding a PNE intervention showed promising 
results, equalling or surpassing previously reported outcomes.
Significance: A structured group intervention based on pain neuroscience education 
for 1 year in patients with fibromyalgia was associated with significant amelioration 
of the impact of the disease on scores of the Fibromyalgia Impact Questionnaire, 
the Health Assessment Questionnaire, the Hospital Anxiety and Depression Scale, 
the Pain Catastrophizing Scale and the Polysymptomatic Distress Scale as compared 
with only treatment as usual. These findings are clinically relevant considering the 
challenges posed by fibromyalgia to clinicians and patients alike.
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2.2 | Patients
Participants in the study were male and female patients 
aged 18  years or older who had been previously diag-
nosed with FM by their attending physicians (e.g. rheu-
matologists, specialists in internal medicine, general 
practitioners, etc.) in any health care setting. The elec-
tronic databases of patients with FM included in the wait-
ing lists for appointments in five primary health care 
centres in the area of Bilbao (Basque country, Spain) 
were used for the selection of patients. Eligible patients 
were initially contacted by telephone and were informed 
regarding the purpose and characteristics of the study; 
those who agreed were appointed for an initial (enrol-
ment) visit at the primary health care centre. At this visit, 
a member of the research team confirmed the diagnosis of 
FM according to 2010 diagnostic criteria of the American 
College of Rheumatology (Wolfe et al., 2010) (i.e. wide-
spread pain index (WPI) ≥ 7 and symptom severity (SS) 
score ≥5 or WPI 3– 6 and SS ≥9, presence of symptoms 
at a similar level for at least 3  months and absence of 
any disorder that would otherwise explain the pain) and 
reviewed the exclusion criteria, which were cognitive im-
pairment or psychiatric disorders that prevented to com-
plete the study questionnaires. Full details of the study 
were provided and enrolled patients signed the written 
informed consent.
2.3 | Randomization
After written informed consent was obtained, enrolled patients 
were randomized to 1 of 2 treatment groups. Randomization 
was performed by the statistical team with the software 
nQuery Advisor version 7.0 (Statistical Solutions, Boston, 
MA, USA). The randomization list generated by this process 
was concealed and safeguarded by the statistical team. The 
research team and treating physicians did not have access 
to this list. Allocation concealment was maintained by the 
use of sequentially numbered opaque envelopes containing 
a letter A (experimental group) or B (control group), follow-
ing the randomization list and were opened by the therapists 
who performed the intervention after enrolment. Each study 
arm was subsequently subdivided into five subgroups, each 
of them (an intervention subgroup and control subgroup) 
assigned to the five participating centres. Patients assigned 
to the intervention arm received a structured pedagogical 
group intervention based on PNE and patients randomized to 
both groups (intervention and control) continued with their 
usual treatments. Neither the patients nor the evaluators were 
blinded to the treatment allocation. However, data managers 
and the statistical team were blinded.
2.4 | Intervention
The theoretical framework of the educational intervention is 
based on PNE to address chronic pain, providing extensive 
explanations of neurobiology and neurophysiology adapted 
for FM patients (Butler & Moseley,  2003; Goicoechea & 
Echávarri, 2009; Goicoechea & Goicoechea, 2019; Louw Pt 
et al. 2016). Briefly, the purpose is to make the person aware 
that there are unconscious automatic mechanisms involved 
in the learning processes, sensitization and acquisition of 
beliefs about pain that can be modulated through conscious 
behaviour. Active participation of the patient is proposed in 
the process of central nervous system (CNS) desensitization 
with his/her attention fostered with the aim of weakening the 
neuronal connections that comprise the pain neuromatrix, 
and establishing new connections thanks to neuroplasticity. 
Likewise, improvement of proprioception was attempted 
with exercises of conscious movement. Work was based on 
the hypothesis of the importance of the information handled 
by the CNS in the threat assessment process as a determining 
factor in the appearance and maintenance of the pain disorder. 
This threat assessment is favoured by unconscious nocicep-
tive learning throughout life, such as the alarmist culture, the 
presence of pain models in the surroundings and the informa-
tion given by expert professionals as sensitizing factors.
Patients were divided into five subgroups of 14 patients 
each. The intervention consisted of six 2- hr weekly classes 
taught by a multidisciplinary team of two or three experi-
enced therapists trained in teaching educational interventions 
to patients with FM, followed by a seventh reinforcement 
class a month later. Therapists who delivered the intervention 
taught the content of each class with the aid of audio- visual 
material. Interspersed in the neurobiology topic were short 
exercises of conscious movement. After each class, support-
ing material was sent to patients by email. The content of 
the classes (Barrenengoa, Gracia, & Martínez de la Eranueva, 
2020) is summarized in the Supplementary material. PNE 
was not associated with physical therapy or use of physical 
exercises and sport, although patients were motivated in this 
direction during the sessions.
Patients both in the intervention and control groups contin-
ued with their usual treatments, with medication adjustments 
made at follow- up visits when necessary by their attending 
physicians (different from the researchers of the study). In 
Spain, the usual treatment for patients with FM is mainly 
pharmacological and adjusted to the symptomatic profile of 
each individual patient, mostly including antidepressants, 
antiepileptics and opioid and nonopioid analgesics. Exercise 
tailored to the patients’ physical limitations are usually rec-
ommended based on recommendations of scientific societies 
summarized in a document issued by the Spanish Ministry of 
Health (Ministerio de Sanidad, 2011).
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2.5 | Study procedures and data collection
The study included a baseline visit, a visit after treatment 
(1 month) and follow- up visits at 6 and 12 months. At the 
baseline visit, clinical history of pain was made, demograph-
ics and clinical data were recorded, and the study question-
naires were completed. At follow- up visits, clinical data 
were recorded and study questionnaires were also completed. 
Visits lasted about 45 min except for the baseline visit in pa-
tients assigned to the intervention arm, in which personal and 
familial history of pain was specifically recorded and lasted 
about 90 min.
Data collected for each patient included demographics 
(age, gender); civil status; number of children; education level 
(categorized as ‘up to secondary school’ and ‘higher level’); 
employment status; age at diagnosis of FM; socioeconomic 
deprivation index (computed by the Health Research Service 
of the Basque country from 2011 census of population and 
housing (Domínguez- Berjón et  al.,  2008) and divided into 
quintiles); the Fibromyalgia Impact Questionnaire (FIQ) 
(Burckhardt et  al.,  1991); the Brief Pain Inventory- Short 
Form (BPI- SF) (Tan et  al.,  2004); the Health Assessment 
Questionnaire (HAQ) (Fries, 1983); the Hospital Anxiety and 
Depression Scale (HADS) (Zigmond et al., 2014); the Pain 
Catastrophizing Scale (PCS) (Sullivan et al., 1995); the WPI 
(Wolfe et  al.,  2010); the SS score (Wolfe et  al.,  2010); the 
Polysymptomatic Distress Scale (PSD) (Wolfe et al., 2013) 
and adverse events in response to direct questioning.
The FIQ is composed of 10 items. The first item contains 
11 questions related to physical functioning (each question 
is rated on a 4- point Likert- type scale). Items 2 and 3 ask 
the patient to mark the number of days they felt well and the 
number of days they were unable to work because of FM 
symptoms. Items 4 through 10 are horizontal linear scales 
marked in 10 increments on which the patient rates work 
difficulty, pain, fatigue, morning tiredness, stiffness, anxiety 
and depression. The maximum possible score is 100, with 
the higher the score, the greater impairment. The BPI- SF is 
an 11- item scale that assesses the severity or intensity of pain 
and its impact on functioning or interference, with 4 BPI se-
verity items and 7 BPI interference items (Tan et al., 2004). 
Higher scores indicate greater severity and interference. The 
HAQ, developed for the assessment of disability in patients 
with rheumatoid arthritis, is composed of 20 questions con-
cerning activities of daily living and 14 questions relating to 
the use of aids and devices. Higher scores mean more severe 
symptoms. The HADS consists of two subscales, anxiety and 
depression (7 items for each subscale), with higher scores 
indicating the most severe symptoms. The PCS consists of 
13 items with three subscales (magnification, rumination 
and helplessness) and scored from 0 to 4, resulting in a total 
possible score of 52. The higher the score, the more cata-
strophizing thoughts are present. The WPI quantifies the ex-
tent of bodily pain on a 0– 19 scale by asking patients if they 
have had pain or tenderness in 19 different body regions over 
the past week, with each painful or tender region scoring 1 
point. The SS final score is the sum of the fatigue, nonre-
storative sleep and cognitive symptom scores in addition to 
‘other symptoms’ score, with a final score ranging between 
0 and 12. The sum of the WPI and the SS score constitutes 
F I G U R E  1  Flow diagram of the study 
population
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the fibromyalgianess scale or PSD, a measure of physical 
and psychological symptom intensity (distress) that can be 
applied to subjects regardless of disease. The study question-
naires were administered by the therapists at each study visit 
using the Spanish validated version of the FIQ (Monterde 
et  al.,  2004), BPI- SF (Arreola Ornelas et  al.,  2012), HAQ 
(Esteve- Vives et al., 1993), HADS (Vallejo et al., 2012) and 
PCS (García Campayo et al., 2008).
2.6 | Outcomes
The primary outcome was the decrease in FIQ scores at the 
end of the study as compared with baseline in patients under-
going the intervention versus controls. Secondary outcomes 
were the decreases in BPI- SF, HAQ, HADS, PCS and PSD 
as well the percentage of responders and nonresponders in 
the two study groups according to a ≥20% reduction in the 
FIQ score from baseline to the end of the study, ≥ 50% reduc-
tion in the FIQ score from baseline to the end of the study and 
number of patients reaching no worse than moderate func-
tional impairment (FIQ score <39) (Luciano et al., 2014).
Losses were defined as participants who did not attend 
more that 50% of the classes and/or those who failed to attend 
the follow- up visit at 12 months.
2.7 | Statistical analysis
Based on a medium effect size of 0.52 for functional status of 
the FIQ reported in a previous meta- analysis of psychologi-
cal treatments for FM (Glombiewski et al., 2010), a sample 
size of 70 patients per group was needed to achieve a 5% 
two- sided significance level and 80% power while account-
ing for a maximum loss rate of 20%. Categorical variables 
were compared with the chi- square test or the Fisher's exact 
test, and continuous variables with the Student's t test, the 
analysis of variance (ANOVA) or the Mann- Whitney U test 
according to the conditions of application. The Bonferroni's 
correction was used to adjust in multiple pairwise compari-
sons. Main analyses of effectiveness were performed in the 
intention- to- treat (ITT) dataset; missing data were handled 
with imputation. Linear mixed- effect regression models were 
used to assess differences in the study variables between the 









Males 2 (2.9) 6 (8.7) 0.139
Females 68 (97.1) 63 (91.3)
Age, years (mean 
[SD])
52.3 (9.2) 51.4 (10.2) 0.845
Civil status (N [%])
Single 10 (14.3) 12 (17.4) 0.725
Married/with 
partner
49 (70) 46 (66.7)
Widowed 1 (1.4) 0
Separate/
divorced
10 (14.3) 11 (15.9)
Number of children (N [%])
None 17 (24.3) 16 (23.2) 0.560
1 22 (31.4) 15 (21.7)
2 26 (37.1) 32 (46.4)
≥3 5 (7.1) 6 (8.7)
Education level (N [%])
Up to secondary 
school
44 (62.9) 46 (66.7) 0.638
Higher 26 (37.1) 23 (33.3)
Deprivation index (N [%])
1– 2 29 (47,5) 21 (31.3) 0.168
3 9 (14.8) 14 (20.9)
4– 5 23 (37.7) 32 (47.8)
Employment status (N [%])
Retired/
invalidity
10 (14.3) 7 (10.1) 0.868
Unemployed/
sick leave
23 (32.9) 26 (37.7)
Active 29 (41.4) 28 (40.6)
Unpaid 
housework
8 (11.4) 8 (11.6)
Age at diagnosis of FM, years (N [%])
≤14 7 (10) 5 (7.2) 0.690
15– 24 15 (21.4) 16 (23.2)
25– 34 16 (22.9) 18 (26.1)
35– 44 20 (28.6) 22 (31.9)
45– 54 7 (10) 7 (10)




[%]). See also 
Figure 2









Antidepressants 33 (47.14) 32 (46.38) 0.928
Anticonvulsants 38 (54.28) 37 (53.62) 0.938
Total analgesics 57 (81.43) 58 (84.06) 0.682
Opioid analgesics 23 (32.86) 23 (33.33) 0.952
T A B L E  1  (Continued)
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intervention and control groups (response variable: score 
of each study questionnaire at follow- up; explanatory vari-
ables: baseline score, group, time and interaction between 
group and time). The effect size was evaluated using Cohen's 
d (d = 0.20 small, d = 0.50 medium and d = 0.80 large ef-
fect sizes respectively). The absolute risk reduction (ARR) 
with the 95% confidence interval (CI) and number needed 
to treat (NNT) with the intervention to achieve response for 
a FIQ score reduction ≥20% and ≥50%, and FIQ total score 
<39 were also calculated. Statistical significance was set 
F I G U R E  2  Details of pharmacological treatment in the study 
groups. No pharmacological treatment, intervention group, n = 4, 
control group, n = 5 (AT, analgesics total, AC, anticonvulsants, AD, 
antidepressants)
F I G U R E  3  Changes of FIQ scores 
during the study period
T A B L E  2  Changes of the Fibromyalgia Impact Questionnaire (FIQ) during the study period
FIQ items




Treatment as usual 
mean (SD)
Cohen´s d ES 
(95% CI)
PNE- based intervention 
mean (SD)
Treatment as usual  
mean (SD)





Treatment as usual 
mean (SD)












3.6 (2.4) 3.6 (2.4) 0.00 
(−0.001– 0.01)
1.4 (1.7) 1.4 (2.4) 0.96 (0.59– 1.55) 1.5 (1.8) 3.4 (2.4) 0.89 (0.54– 1.45) 1.6 (1.9) 3.2 (2.4) 0.74 (0.43– 1.22)
Days felt good 8.3 (2.9) 8.3 (2.4) 0.07 
(−0.01– 0.19)
4.5 (3.7) 8.7 (2.2) 1.38 (0.89– 2.18) 5.0 (4.0) 8.5 (2.5) 1.05 (0.66– 1.69) 5.3 (3.9) 8.0 (2.9) 0.78 (0.46– 1.29)
Pain influencing 
work
6.1 (2.0) 5.9 (2.2) 0.09 
(−0.002– 0.21)
3.3 (3.5) 6.9 (2.3) 1.21 (0.78– 1.94) 3.0 (3.2) 5.8 (2.6) 0.96 (0.59– 1.55) 3.4 (3.2) 5.4 (2.6) 0.68 (0.39– 1.39)
Pain 7.3 (2.3) 7.2 (2.0) 0.04 
(−0.02– 0.11)
5.0 (2.8) 7.6 (1.7) 1.22 (0.71– 1.79) 5.1 (2.9) 6.6 (2.3) 0.57 (0.31– 0.97) 4.9 (2.8) 7.3 (2.0) 0.98 (0.61– 1.59)
Fatigue 8.2 (1.9) 8.1 (1.9) 0.05 
(−0.02– 0.14)
5.1 (3.1) 8.1 (1.8) 1.18 (0.75– 1.89) 5.2 (3.4) 7.6 (1.8) 0.88 (0.53– 1.43) 5.1 (3.3) 7.4 (1.9) 0.85 (0.51– 1.39)
Morning 
tiredness
7.9 (2.2) 7.8 (2.5) 0.04 
(−0.02– 0.12)
5.0 (3.5) 8.0 (2.0) 1.05 (0.66– 1.69) 5.0 (3.6) 7.4 (2.5) 0.77 (0.45– 1.27) 4.7 (3.2) 7.0 (2.5) 0.80 (0.47– 1.31)
Stiffness 7.4 (2.8) 7.2 (2.7) 0.07 
(−0.01– 0.18)
4.0 (3.2) 6.9 (3.0) 0.93 (0.57– 1.51) 4.8 (3.4) 6.5 (2.7) 0.65 (0.37– 1.09) 4.3 (3.4) 6.4 (2.7) 0.68 (0.39– 1.13)
Anxiety 7.0 (2.6) 7.3 (2.4) 0.12 (0.01– 0.26) 4.7 (3.3) 6.9 (3.0) 0.69 (0.39– 1.16) 4.5 (3.4) 6.7 (2.6) 0.73 (0.42– 1.20) 4.5 (3.5) 7.0 (2.5) 0.82 (0.49– 1.34)
Depression 6.7 (3.0) 6.7 (3.0) 0.00 
(−0.001– 0.01)
3.5 (3.4) 6.5 (3.0) 0.93 (0.57– 1.51) 3.7 (3.6) 6.4 (2.9) 0.82 (0.49– 1.35) 3.9 (3.6) 6.1 (3.1) 0.65 (0.37– 1.09)
FIQ total score 60.9 (15.3) 60.1 (13.8) 0.05 
(−0.02– 0.14)
36.5 (21.8) 60.6 (12.8) 1.35 (0.88– 2.14) 38.0 (24.2) 57.0 (14.3) 0.95 (0.59– 1.55) 37.4 (24.1) 56.7 (15.6) 0.95 (0.58– 1.54)
Note: PNE, pain Neurobiology Education; SD, standard deviation; ES, effect size; CI, confidence interval.
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at p  <  .05. SPSS version 23.0 and SAS version 9.3 (SAS 
Institute) were used for statistical analysis.
3 |  RESULTS
From a total of 225 eligible patients diagnosed with FM, 156 
(69.3%) were contacted by phone and 140 (89%) of them agreed 
to participate in the study. The remaining 16 patients refused 
for several reasons including working, maternity, surgical pro-
cedure or hospital admission. As shown in the flow diagram of 
the study population (Figure 1), of the 140 patients randomized, 
70 were assigned to the intervention group and 70 to the control 
group. One patient in the control group did not attend the base-
line visit. At follow- up, two patients from each group were lost 
(did not attend at least 50% of classes and/or the 12- month fol-
low- up). The ITT dataset included 70 patients in the interven-
tion group (97.1%, n = 68, completed the study) and 69 in the 
control group (95.7%, n = 67, completed the study). More than 
90% of patients were women with a mean age of 51.9 years. 
As shown in Table 1, significant differences in baseline char-
acteristics of patients between the two study groups were not 
found. Differences in the use of pharmacological medications 
were not found. Details of pharmacological treatment regarding 
the number of patients treated with total analgesics, anticonvul-
sants and antidepressants are shown in Figure 2.
3.1 | Primary outcome
As shown in Figure  3, the intervention was significantly 
more effective than treatment as usual for improving mean 
total score of the FIQ (p < .001). The comparison of results 
in the different items of the FIQ instrument between the in-
tervention and the control groups showed large effect sizes 
in all dimensions and in the total score, except for a medium 
effect size for anxiety (Table  2). At 12  months, the effect 
sizes of the differences between the intervention and the con-
trol groups were large for pain, fatigue, morning tiredness, 
anxiety and FIQ total score, and medium for the remaining 
dimensions.
3.2 | Secondary outcomes
The intervention was also more effective than treatment as 
usual with differences in BPI (severity and interference), HAD 
(anxiety and depression), HAQ, PCS and PSD (Figure  4). 
As shown in Table 3, the effect size of the intervention after 
1 month of treatment was large in all questionnaires, except 
for the HAD subscale depression in which the effect size was 
medium. At the end of the study, after 12 months, the effect 
size of the intervention was large in all questionnaires, except 
for medium effect sizes in HAD subscale anxiety and HAQ.
T A B L E  2  Changes of the Fibromyalgia Impact Questionnaire (FIQ) during the study period
FIQ items




Treatment as usual 
mean (SD)
Cohen´s d ES 
(95% CI)
PNE- based intervention 
mean (SD)
Treatment as usual  
mean (SD)





Treatment as usual 
mean (SD)












3.6 (2.4) 3.6 (2.4) 0.00 
(−0.001– 0.01)
1.4 (1.7) 1.4 (2.4) 0.96 (0.59– 1.55) 1.5 (1.8) 3.4 (2.4) 0.89 (0.54– 1.45) 1.6 (1.9) 3.2 (2.4) 0.74 (0.43– 1.22)
Days felt good 8.3 (2.9) 8.3 (2.4) 0.07 
(−0.01– 0.19)
4.5 (3.7) 8.7 (2.2) 1.38 (0.89– 2.18) 5.0 (4.0) 8.5 (2.5) 1.05 (0.66– 1.69) 5.3 (3.9) 8.0 (2.9) 0.78 (0.46– 1.29)
Pain influencing 
work
6.1 (2.0) 5.9 (2.2) 0.09 
(−0.002– 0.21)
3.3 (3.5) 6.9 (2.3) 1.21 (0.78– 1.94) 3.0 (3.2) 5.8 (2.6) 0.96 (0.59– 1.55) 3.4 (3.2) 5.4 (2.6) 0.68 (0.39– 1.39)
Pain 7.3 (2.3) 7.2 (2.0) 0.04 
(−0.02– 0.11)
5.0 (2.8) 7.6 (1.7) 1.22 (0.71– 1.79) 5.1 (2.9) 6.6 (2.3) 0.57 (0.31– 0.97) 4.9 (2.8) 7.3 (2.0) 0.98 (0.61– 1.59)
Fatigue 8.2 (1.9) 8.1 (1.9) 0.05 
(−0.02– 0.14)
5.1 (3.1) 8.1 (1.8) 1.18 (0.75– 1.89) 5.2 (3.4) 7.6 (1.8) 0.88 (0.53– 1.43) 5.1 (3.3) 7.4 (1.9) 0.85 (0.51– 1.39)
Morning 
tiredness
7.9 (2.2) 7.8 (2.5) 0.04 
(−0.02– 0.12)
5.0 (3.5) 8.0 (2.0) 1.05 (0.66– 1.69) 5.0 (3.6) 7.4 (2.5) 0.77 (0.45– 1.27) 4.7 (3.2) 7.0 (2.5) 0.80 (0.47– 1.31)
Stiffness 7.4 (2.8) 7.2 (2.7) 0.07 
(−0.01– 0.18)
4.0 (3.2) 6.9 (3.0) 0.93 (0.57– 1.51) 4.8 (3.4) 6.5 (2.7) 0.65 (0.37– 1.09) 4.3 (3.4) 6.4 (2.7) 0.68 (0.39– 1.13)
Anxiety 7.0 (2.6) 7.3 (2.4) 0.12 (0.01– 0.26) 4.7 (3.3) 6.9 (3.0) 0.69 (0.39– 1.16) 4.5 (3.4) 6.7 (2.6) 0.73 (0.42– 1.20) 4.5 (3.5) 7.0 (2.5) 0.82 (0.49– 1.34)
Depression 6.7 (3.0) 6.7 (3.0) 0.00 
(−0.001– 0.01)
3.5 (3.4) 6.5 (3.0) 0.93 (0.57– 1.51) 3.7 (3.6) 6.4 (2.9) 0.82 (0.49– 1.35) 3.9 (3.6) 6.1 (3.1) 0.65 (0.37– 1.09)
FIQ total score 60.9 (15.3) 60.1 (13.8) 0.05 
(−0.02– 0.14)
36.5 (21.8) 60.6 (12.8) 1.35 (0.88– 2.14) 38.0 (24.2) 57.0 (14.3) 0.95 (0.59– 1.55) 37.4 (24.1) 56.7 (15.6) 0.95 (0.58– 1.54)
Note: PNE, pain Neurobiology Education; SD, standard deviation; ES, effect size; CI, confidence interval.
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F I G U R E  4  Changes of scores in the 
BPI- SF severity and interference, HAD 
anxiety and depression, HAQ, PCS and PSD 







Baseline 1 month aer
treatment
6 months follow-up 12 months follow-up
PNE-based intervenon
Treatment as usual (control)
Group x me interacon
Variable F stasc P value
PSD 21.72 <0.001
T A B L E  3  Changes of the Brief Pain Inventory- Short Form (BPI- SF), the Health Assessment Questionnaire (HAQ), the Hospital Anxiety  
and Depression Scale (HADS), the Pain Catastrophizing Scale (PCS), the Widespread Pain Index (WPI), the Symptom Severity (SS) and the  
Polysymptomatic Distress Scale (PSD) during the study period
Questionnaires














Cohen´s d ES 
 (95% CI)
PNE- based intervention 
mean (SD)
Treatment as usual 
mean (SD)
Cohen´s d ES 
(95% CI)
PNE- based intervention 
mean (SD)
Treatment as usual 
mean (SD)
Cohen´s d ES 
(95% CI)
BPI severity 5.8 (1.7) 5.6 (1.7) 0.12 
(−0.02– 0.11)
3.5 (1.9) 5.7 (1.7) 1.22 (0.78– 1.94) 4.0 (2.2) 5.2 (1.9) 0.58 (0.32– 0.98) 3.7 (2.2) 5.5 (1.8) 0.89 
(0.54– 1.45)
BPI interference 6.6 (2.2) 6.4 (2.2) 0.09 
(−0.004– 0.21)
3.5 (2.7) 6.6 (2.2) 1.25 (0.81– 2.00) 3.6 (2.7) 5.7 (2.2) 0.85 (0.51– 1.39) 3.5 (2.7) 5.9 (2.3) 0.95 
(0.59– 1.55)
HDA anxiety 13.1 (3.9) 12.3 (4.2) 0.19 (0.05– 0.38) 8.4 (4.6) 11.8 (4.3) 0.76 (0.45– 1.25) 8.7 (4.9) 11.8 (4.1) 0.68 (0.39– 1.39) 8.2 (4.2) 11.9 (4.1) 0.89 
(0.54– 1.45)
HDA depression 9.5 (4.4) 9.2 (4.0) 0.07 
(−0.01– 0.17)
1.3 (0.9) 2.4 (2.4) 0.60 (0.33– 1.01) 4.9 (4.5) 9.3 (4.5) 0.98 (0.60– 1.58) 5.1 (4.9) 8.8 (4.7) 0.77 
(0.45– 1.26)
HAQ 1.4 (0.5) 1.3 (0.6) 0.18 (0.04– 0.36) 0.6 (0.5) 1.1 (0.6) 0.90 (0.55– 1.47) 0.6 (0.5) 1.0 (0.6) 0.72 (0.42– 1.19) 0.7 (0.5) 1.1 (0.6) 0.54 
(0.29– 0.92)
PCS 26.9 (14.6) 24.4 (13.0) 0.18 (0.04– 0.3) 11.0 (11.3) 25.5 (15.7) 1.06 (0.66– 1.70) 11.6 (12.8) 23.8 (14.2) 0.90 (0.54– 1.46) 10.6 (12.3) 23.3 (15.5) 0.91 
(0.55– 1.47)
PSD 25.6 (2.8) 24.9 (3.1) 0.23 (0.07– 0.4) 13.5 (6.4) 21.3 (5.1) 1.34 (0.9– 2.1) 14.7 (7.4) 20.7 (5.7) 0.90 (0.5– 1.4) 14.0 (7.4) 21.6 (5.5) 1.16 (0.7– 1.8)
WPI 17.3 (2.2) 16.6 (2.5) 0.30 (0.1– 0.5) 8.3 (4.5) 13.4 (3.9) 0.21 (0.06– 0.4) 9.4 (5.0) 13.1 (4.5) 0.78 (0.5– 1.3) 8.9 (5.1) 13.6 (4.0) 1.02 (0.6– 1.6)
SS 8.3 (1.0) 8.3 (1.0) 0 5.2 (2.5) 7.9 (1.9) 1.22 (0.8– 1.9) 5.3 (2.9) 7.9 (1.9) 1.06 (0.7– 1.7) 5.1 (2.9) 8.0 (2.0) 1.16 (0.8– 1.8)
Note: PNE: pain neurobiology education; SD: standard deviation; ES: effect size; CI: confidence interval.
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The number of responders with a reduction in the total 
FIQ score ≥20% and ≥50%, and FIQ score <39 points was 
significantly higher (p  <  .001) in the intervention group 
as compared with controls at each time point of the study 
(Table 4). Also, the intervention was associated with ARR of 
49.7% (95% CI 37.3– 65.9) and NNT of 2.01 (95% CI 1.99– 
2.03) for a ≥20% reduction in the total FIQ score, ARR of 
35.2% (95% CI 34.8– 35.6) and NNT of 2.83 (95% CI 2.80– 
2.87) for a ≥50% reduction in total FIQ score, and ARR of 
39.5% (95% CI 39– 39.9) and NNT of 2.53 (95% CI 2.50– 
2.56) for a total FIQ score <39.
4 |  DISCUSSION
This randomized controlled trial shows that a structured group 
intervention based on PNE was effective in reducing the im-
pact of FM on pain, anxiety and catastrophizing thoughts as 
compared with treatment as usual only. Significant improve-
ments were already seen after 1 month of treatment and were 
sustained over the 6- month and 12- month follow- up periods.
The effect sizes for the difference between the interven-
tion control groups were large/medium for almost of compo-
nents of the study questionnaires, particularly pain, fatigue and 
morning tiredness of the FIQ, pain severity and interference 
of the BPI- SF, anxiety of the HAD and catastrophism of the 
PCS. These findings are clinically relevant and confirm data 
of a before- and- after study carried out in 85 patients with FM 
and previously reported by our group (Barrenengoa- Cuadra 
et al., 2021). In a randomized controlled trial, a similar primary 
care- based group educational intervention adapted to migraine 
compared to the routine medical care was effective in prevent-
ing migraine attacks and cost- effective in reducing the need for 
pharmacological treatment (Aguirrezabal et al., 2019).
In a cost- effectiveness analysis of pharmacological treat-
ment options in FM, the use of pregabalin was associated 
with a reduction in FIQ total score ≥30% in 31.6% of the 
cases (Arreola Ornelas et  al.,  2012), whereas in our study, 
a reduction of ≥50% was achieved in 39.7% of the patients. 
On the other hand, an in- depth review of pharmacological 
therapies in fibromyalgia syndrome showed that the majority 
of drug medications have a modest effect, with substantial 
benefit in only a minority of patients (Häuser et al., 2014). 
Also, most patients will discontinue therapy because of either 
a lack of efficacy or tolerability problems. The promising 
results of the present study are consistent with recommen-
dations that the initial management of FM should involve 
patient education proposed in the European League Against 
Rheumatism (EULAR) revised guidelines for managing FM 
(Macfarlane et al., 2017).
In a 6- month randomized controlled trial of group accep-
tance and commitment therapy (EFFIGACT study) (Luciano 
et al., 2014), the NNT for 50% improvement in the FIQ total 
score was 46 and for achieving a status of no worse than mild 
impaired function (FIQ total score <39) also 46. These data 
are notably more unfavourable that NNT of 2.8 and 2.5 ob-
tained in our study for FIQ ≥50% and FIQ <39, respectively.
Results of a systematic review of randomized controlled 
trials of PNE in patients with musculoskeletal disorders, sup-
port the use of PNE in reducing pain and improving patient 
knowledge of pain, improving function and lowering dis-
ability, reducing psychosocial factors, enhancing movement 
T A B L E  3  Changes of the Brief Pain Inventory- Short Form (BPI- SF), the Health Assessment Questionnaire (HAQ), the Hospital Anxiety  
and Depression Scale (HADS), the Pain Catastrophizing Scale (PCS), the Widespread Pain Index (WPI), the Symptom Severity (SS) and the  
Polysymptomatic Distress Scale (PSD) during the study period
Questionnaires














Cohen´s d ES 
 (95% CI)
PNE- based intervention 
mean (SD)
Treatment as usual 
mean (SD)
Cohen´s d ES 
(95% CI)
PNE- based intervention 
mean (SD)
Treatment as usual 
mean (SD)
Cohen´s d ES 
(95% CI)
BPI severity 5.8 (1.7) 5.6 (1.7) 0.12 
(−0.02– 0.11)
3.5 (1.9) 5.7 (1.7) 1.22 (0.78– 1.94) 4.0 (2.2) 5.2 (1.9) 0.58 (0.32– 0.98) 3.7 (2.2) 5.5 (1.8) 0.89 
(0.54– 1.45)
BPI interference 6.6 (2.2) 6.4 (2.2) 0.09 
(−0.004– 0.21)
3.5 (2.7) 6.6 (2.2) 1.25 (0.81– 2.00) 3.6 (2.7) 5.7 (2.2) 0.85 (0.51– 1.39) 3.5 (2.7) 5.9 (2.3) 0.95 
(0.59– 1.55)
HDA anxiety 13.1 (3.9) 12.3 (4.2) 0.19 (0.05– 0.38) 8.4 (4.6) 11.8 (4.3) 0.76 (0.45– 1.25) 8.7 (4.9) 11.8 (4.1) 0.68 (0.39– 1.39) 8.2 (4.2) 11.9 (4.1) 0.89 
(0.54– 1.45)
HDA depression 9.5 (4.4) 9.2 (4.0) 0.07 
(−0.01– 0.17)
1.3 (0.9) 2.4 (2.4) 0.60 (0.33– 1.01) 4.9 (4.5) 9.3 (4.5) 0.98 (0.60– 1.58) 5.1 (4.9) 8.8 (4.7) 0.77 
(0.45– 1.26)
HAQ 1.4 (0.5) 1.3 (0.6) 0.18 (0.04– 0.36) 0.6 (0.5) 1.1 (0.6) 0.90 (0.55– 1.47) 0.6 (0.5) 1.0 (0.6) 0.72 (0.42– 1.19) 0.7 (0.5) 1.1 (0.6) 0.54 
(0.29– 0.92)
PCS 26.9 (14.6) 24.4 (13.0) 0.18 (0.04– 0.3) 11.0 (11.3) 25.5 (15.7) 1.06 (0.66– 1.70) 11.6 (12.8) 23.8 (14.2) 0.90 (0.54– 1.46) 10.6 (12.3) 23.3 (15.5) 0.91 
(0.55– 1.47)
PSD 25.6 (2.8) 24.9 (3.1) 0.23 (0.07– 0.4) 13.5 (6.4) 21.3 (5.1) 1.34 (0.9– 2.1) 14.7 (7.4) 20.7 (5.7) 0.90 (0.5– 1.4) 14.0 (7.4) 21.6 (5.5) 1.16 (0.7– 1.8)
WPI 17.3 (2.2) 16.6 (2.5) 0.30 (0.1– 0.5) 8.3 (4.5) 13.4 (3.9) 0.21 (0.06– 0.4) 9.4 (5.0) 13.1 (4.5) 0.78 (0.5– 1.3) 8.9 (5.1) 13.6 (4.0) 1.02 (0.6– 1.6)
SS 8.3 (1.0) 8.3 (1.0) 0 5.2 (2.5) 7.9 (1.9) 1.22 (0.8– 1.9) 5.3 (2.9) 7.9 (1.9) 1.06 (0.7– 1.7) 5.1 (2.9) 8.0 (2.0) 1.16 (0.8– 1.8)
Note: PNE: pain neurobiology education; SD: standard deviation; ES: effect size; CI: confidence interval.
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and minimizing health care utilization (Louw et al., 2016). 
Evidence of the use of PNE in patients with FM is scarce. 
In a double- blind randomized controlled trial, intensive pain 
physiology education versus pacing self- management educa-
tion was associated with significant differences in improve-
ments in physical functioning, vitality, mental health, general 
health perceptions and lower pain scores (Van Oosterwijck 
et  al.,  2013). In another 6- month randomized double- blind 
multicentre study, written pain neuroscience education com-
pared to written relaxation training, did not change the impact 
of FM on daily life, catastrophizing or perceived symptoms 
of patients with FM (Van Ittersum et  al.,  2014). The study 
concluded that face- to- face sessions of pain neuroscience 
education are required to change inappropriate cognitions 
and perceived health in patients with FM (Van Ittersum 
et al., 2014). In a single- blind randomized trial of 77 patients 
with FM, PNE leads to improvements in pain intensity and 
this improvement was correlated with the duration of the PNE 
received (6 weekly, 45- min group sessions) (Amer- Cuenca 
et  al.,  2019). However, the intervention of our study has a 
longer duration than “high doses of PNE” described by the 
authors (Amer- Cuenca et al., 2019), which could be relevant 
when interpreting better results obtained in the present study.
Our intervention programme, as well as containing in-
formation about the neurobiology of pain in common with 
other published interventions based on PNE (Amer- Cuenca 
et  al.,  2019; Van Oosterwijck et  al.,  2013), adds the con-
cept of cerebral- acquired evaluation error (Goicoechea & 
Echávarri,  2009; Goicoechea & Goicoechea,  2019). This 
novel approach incorporates as a sensitizing factor with un-
conscious nociceptive lifelong learning involved in the etio-
pathogenetic mechanisms of FM. The symptoms would arise 
because of an erroneous assessment of danger by the neuro-
nal network. Such an error would be arrived at by multiple 
and complex mechanisms that define biological learning. We 
maintain that the alarmist culture, the opinion of experts, the 
copying of models and erroneous beliefs about one's own or-
ganism are major components of this erroneous evaluation 
process. We consider that the modification of PNE with this 
concept makes for the great relevance of the results obtained 
because education in neuroscience leads to new, conscious 
learning, which can change the previous evaluative errors and 
enable the patients to modify the confrontation of their symp-
toms and engage in the gradual re- exposure to activity.
The present findings should be interpreted taking into 
account some limitations, particularly the open- label de-
sign, the absence of an active control group and the lack of 
control of the pharmacologic treatment. The intervention 
was known by both evaluators and patients, so that a detec-
tion bias in favour of the intervention group cannot be ex-
cluded given the subjective component of responses to the 
questionnaires; data managers and the statistical team were 
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absence of an active control group receiving an interven-
tion of similar characteristics (structure and duration) does 
not allow assessing whether or not part of the effect of the 
intervention was nonspecific related to the care provided 
by the team of therapists, regardless of the content of the 
intervention itself. This uncertainty is frequent in clinical 
trials especially in pragmatic trials, in which nonpharma-
cological therapies are evaluated in clinical settings in 
which the usual care does not include similar interventions 
(as in this study) and nonactive control groups are used 
(treatment as usual, usual care or waiting list) (Bernardy 
et al., 2018; Glombiewski et al., 2010; Häuser et al., 2009). 
This approach, however, increases the external validity of 
the study and facilitates the clinical applicability of results 
in other settings (Freedland et al., 2011). A further limita-
tion is the lack of control of the pharmacological treatment. 
This could be considered a critical methodological problem 
present in the majority of clinical trials evaluating nonphar-
macological interventions in FM (Bernardy et  al.,  2018; 
Häuser et al., 2009). Also, ethical considerations are added 
to the practical difficulties regarding the control of medi-
cation mainly due to the presence of frequent comorbidi-
ties increasing the risk of overlapping medication. In this 
respect, the possibility of limiting treatment adjustments 
could have a negative impact on the patients’ health and 
functionality. In the present study, attending physicians 
responsible for the patients’ pharmacological treatment 
were unrelated to the intervention and, therefore, it is un-
likely that assignment of patients to either of the two arms 
would have had an influence on medication adjustments. 
However, the impact of medication adjustments on differ-
ences between both study groups cannot be excluded.
It is important to consider that the moderate to high ef-
fect sizes observed in the intervention group were also due 
to the fact that there was no change from baseline to the 
end of the study in the treatment as usual group, with the 
large width of most 95% CI influencing on the precision 
of the results. Accordingly, in the worst case scenario, the 
effect sizes would have been small to moderate. However, 
the magnitude of the effect of the intervention in real- world 
conditions should be assessed in further trials with better 
designs.
It is unknown whether or not patients in both study 
groups followed recommendations of physiotherapy and 
physical exercise (or other complementary therapies) and 
how involvement in these activities by the patient's own de-
cision could have exerted an influence on the outcomes of 
the study. However, this situation occurs frequently in other 
similar studies (Alda et al., 2011; Galan- martin et al., 2020; 
Glombiewski et al., 2010). The influence of the format of de-
livery (group only) was not assessed, although results of nat-
uralistic study showed the outcome equivalence of group and 
individual therapy (Burlingame et  al.,  2016). On the other 
hand, the influence of treatment expectations and satisfaction 
on outcomes was not evaluated, but this interesting aspect 
may be considered in future studies.
5 |  CONCLUSIONS
Although results should be interpreted with an understanding 
of the study limitations, the improvement in quality of life 
and control of symptoms obtained by adding a PNE inter-
vention in this patients' sample was significant, equalling or 
surpassing previously reported outcomes.
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